


14 **Supplementary data**

15



16

17 **Supplementary Figure S1** IL-6 induces migration, invasion, and epithelial-to-mesenchymal

18 transition (EMT) of colorectal cancer cells *in vitro* and promotes metastasis of colorectal

19 cancer cells *in vivo*. (A) Western blot analysis of E-cadherin and vimentin proteins after

20 treatment of 20 ng/mL IL-6 for indicated periods. (B) Immunofluorescence staining of

21 E-cadherin and vimentin in HT-29 and SW480 cells treated with 20 ng/mL IL-6 for 72 h

22 (nuclei stained with DAPI). Scale bar, 20 μ m. (C) Migration and invasion of SW480 cells

23 treated with IL-6 (20 ng/mL) for 48 h were detected by Transwell assay. The number of

24 migrated and invaded cells is shown in the histogram. (D) Wound healing (scratch) assay of

25 HT-29 cells treated with IL-6 (20 ng/mL) for 24 h. (E) Formation of lung metastases 8 weeks



26 after tail-vein injection of control and IL-6-pretreated (5 days) SW480 cells in NOD/SCID

27 mice. Representative images of the entire lungs and quantification of lung microscopic

28 nodules per mouse are shown (n = 6 from each group). Error bars represent S.E.M. * $P < 0.05$,

29 * $P < 0.01$.

30



31

32 **Supplementary Figure S2** Treatment with IL-6 results in changes in nuclear Trx-1 and



33 pSTAT3 protein levels. (A) Immunofluorescence staining of Trx-1 in HT-29 and SW480 cells

34 treated with 20 ng/mL IL-6 for the indicated periods (nuclei stained with DAPI). Scale bar, 20

35 μ m. (B) The relative levels of nuclear Trx-1 and pSTAT3 in HT-29 and SW480 cells treated

36 with 20 ng/mL IL-6 for the indicated time periods.

37



38


39 **Supplementary Figure S3** Nuclear translocation of Trx-1 is required for IL-6-induced CRC

40 cell migration. (A) Wound healing (scratch) assay of HT-29 cells expressing control vector,

41 WT-Trx-1, MT-Trx-1, or shTrx-1 treated with IL-6 (20 ng/mL) for 24 h. (B) Percentage of

42 relative wound closure after 24 h. Scale bar, 100 μ m. ** $P < 0.01$, * $P < 0.05$.

43



44

45 **Supplementary Figure S4** Genome-wide Trx-1-induced changes in STAT3 occupancy.

46 STAT3 ChIP-seq and RNA-seq were performed in SW480 cells transfected with

47 control-vector, Trx-1, or shTrx-1, and treated with IL-6 (20 ng/mL) for 2 h. (A) Signal of

48 ChIP-seq peaks 3 kb upstream and downstream of transcription start sites (TSS). (B) Clusters

49 of genes with similar expression patterns. The associated genes with differential peaks among

50 three comparisons in ChIP-seq were overlapped with the genes with differential expression in

51 RNA-seq between cells transfected with Vector and Trx-1 to obtain the target genes. The

52 expression patterns of the target genes were analysed using the Mfuzz R package. Based on

53 the similarity of the expression patterns, two clusters were identified, showing that changes in


54 the STAT3 ChIP-seq coverage often lead to transcription alteration.

55

56


57

58



59
60 **Supplementary Figure S5** Knockdown of IL-6 or STAT3 suppresses Trx-1 expression. (A)
61 Western blot analysis of IL-6, STAT3 and Trx-1 expression in HT-29 and SW480 cells
62 transduced with lenti-shIL-6 or lenti-shLuc (control). (B) Western blot analysis of STAT3 and
63 Trx-1 expression in HT-29 and SW480 cells transfected with siSTAT3 or negative control
64 (NC) for 48 h.

65



66

67 **Supplementary Figure S6** The effect of Karyopherin $\alpha 1$ (Kpn $\alpha 1$) knockdown on STAT3 and


68 Trx-1 expressions. (A) Real-time PCR analysis of IL-6, STAT3 and Trx-1 expression in

69 HT-29 and SW480 cells transfected with Karyopherin $\alpha 1$ siRNA (siKpn $\alpha 1$) or negative

70 control (NC) for 48 h. (B) Western blot analysis of STAT3 and Trx-1 expression in HT-29 and

71 SW480 cells transfected with siKpn $\alpha 1$ or NC for 48 h. ns, not significant.

72



73

74

75 **Supplementary Figure S7** PX-12 treatment induces a decrease of nuclear pSTAT3 and Trx-1


76 expressions in HT-29 cells treated with IL-6 for 2 h.

77

78

79

80





81

82 **Supplementary Figure S8** H&E-stained sections of colons from control group, AOM/DSS

83 model mice at 3 week, AOM/DSS model mice at 11 week and AOM/DSS model mice with

84 PX-12 treatment. Scale bars, 100 μ m.

85



87 **Supplementary Figure S9** Generation of mutant Txn1(KK81-82EE)-knockin mice via
 88 CRISPR/Cas9 technology. (A) Diagram of mouse Txn1 exon4 gRNA. The gRNA sequence is
 89 underlined. The sequence of the protospacer adjacent motif (PAM) is indicated in red. (B)
 90 Txn1 genomic sequence of F1 generation mutant (MT) Txn1 (KK81-82EE)-knockin and
 91 wild-type (WT) mice. (Top) DNA sequences of WT mouse. (Bottom) DNA sequences of
 92 MT-Txn1 (KK81-82EE)-knockin (+/-), three point mutations (AAAAAG to GAGGAG) in
 93 one allele.
 94

95 **Supplementary Table S1** Primers used for real-time PCR analysis

Gene	Primer sequence (5'-3')
GAPDH forward:	CCAGCCGAGCCACATCGCTC
GAPDH reverse:	ATGAGCCCCAGCCTTCTCCAT
IL-6 forward:	GGTACATCCTCGACGGCATCT
IL-6 reverse:	GT GCCTCTTTGCTGCTTTCAC
STAT3 forward:	GGACTTCCCGGACAGTGAG
STAT3 reverse:	ATCGCTTGTGTTGCCAGAG
Trx-1 forward:	CAACCCTTTCTTTCATTCCCTCT
Trx-1 reverse:	CACCCACCTTTTGTCCCTTCT

96

97 **Supplementary Table S2** The nuclear/cytosolic Trx-1 ratio after IL-6 treatment for the
98 indicated time

IL-6 (20 ng/mL) stimulation	nuclear/cytosolic Trx-1 ratio	
	HT-29 cells	SW480 cells
0 h	1	1
1 h	8	5
2 h	10	6.8
4 h	2.13	1.83
6 h	0.95	1.1
8 h	0.5	1.5

99

100 **Supplementary Table S3** Lung metastasis nodules in a xenograft mouse model with SW480
 101 cells stably expressing WT-Trx-1 or MT-Trx-1

	Days	Mice with metastasis	Number of lung metastasis nodules		
			< 0.5 mm	> 0.5 mm	Total
WT-Trx-1	56	5/6	28	10	38
WT-Trx-1+IL-6	56	6/6	44	32	76
MT-Trx-1	56	1/6	9	1	10
MT-Trx-1+IL-6	56	2/6	16	3	19

102

103 **Supplementary Table S4** Correlation of Trx-1 and pSTAT3 nuclear expression in 157 human
 104 colorectal cancer tissues

		pSTAT3 nuclear staining			<i>p</i> value
		Cases	Negative	Positive	
Cases			41	116	
Trx-1 nuclear staining	Negative	92	30 (73%)	62 (53%)	0.0275*
	Positive	65	11 (27%)	54 (47%)	

105 **P* < 0.05.

106 **Supplementary Table S5** Association of Trx-1 nuclear expression and clinic pathological
 107 parameters in human colorectal cancer tissues

Variables	Trx-1 nuclear staining			<i>p</i> values
	All cases (n = 157)	Negative (n = 92)	Positive (n = 65)	
Age(year)				
< 65	58	34	24	0.997
≥ 65	99	58	41	
Clinical stage				
I-II	69	40	29	0.88
III-IV	88	52	36	
pN Status				
N0	75	58	17	< 0.001***
N1-N2	82	34	48	
Metastasis				
M0	126	81	45	0.004**
M1	31	11	20	
Tumor site				
Proximal	30	19	11	0.034*
Colon distal	54	38	16	
Colon rectum	73	35	38	

108 **P* < 0.05, ***P* < 0.01, ****P* < 0.001.

109 **Supplementary methods**

110 **Wound healing scratch assay**

111 The cells studied were cultured for 24 h, and a scratch was introduced into the confluent cell
112 layer with a 200 μ l pipette tip. Cells were washed three times with medium to remove
113 detached cells and then incubated with IL-6 for 24 h. Photographs were taken at each time
114 point under a phase contrast microscope (Olympus).

115

116 **Metastasis in a xenograft mouse model**

117 Male NOD/SCID mice (6-8 weeks old) were provided by Shanghai Slaccas Animal Center.
118 SW480 cells expressing the wild type Trx-1 gene (SW480-WT-Trx-1) or mutant Trx-1
119 (SW480-MT-Trx-1) were pretreated with vehicle or IL-6 (20 ng/mL) for 5 days, and then the
120 cells ($4 \times 10^6/0.2$ mL) were injected into the tail vein of NOD/SCID mice. Ten weeks after
121 injection into the tail vein, the mice were sacrificed, and the metastatic nodules in the lungs
122 were examined. All experiments were approved by the Animal Experimental Ethics
123 Committee of Wenzhou Medical University.

124